References
Fernandes NF, Rozdeba PJ, Schwartz RA, Kihiczak G, Lambert WC. Pityriasis lichenoides et varioliformis acuta: a disease spectrum. Int J Dermatol 2010; 49: 257–61.
Bellinato F, Maurelli M, Gisondi P, Girolomoni G. A systematic review of treatments for pityriasis lichenoides. J Eur Acad Dermatol Venereol 2019; 33: 2039–49.
Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol 2022: 1–12.
Magro C, Crowson AN, Kovatich A, Burns F. Pityriasis lichenoides: a clonal T-cell lymphoproliferative disorder. Hum Pathol 2002; 33: 788–95.
Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol 2015; 135: 626–35.
Simon D, Boudny C, Nievergelt H, Simon H, Braathen LR. Successful treatment of pityriasis lichenoides with topical tacrolimus. Br J Dermatol 2004; 150: 1033–5.
Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995; 15: 121–9.
Steck O, Bertschi NL, Luther F, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol 2021; 35: 1331–7.
Funding
Funding: this research received specific grants from funding agencies in the Natural Science Foundation of Fujian Province (2019J01060945) and Intramural funds of C (2021XH026).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest: none.
About this article
Cite this article
Zheng, Y., Liao, L., Yang, H. et al. Successful therapy with dupilumab for pityriasis lichenoides et varioliformis acuta. Eur J Dermatol 33, 304–305 (2023). https://doi.org/10.1684/ejd.2023.4483
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2023.4483